122 results
Page 2 of 7
8-K
EX-99.1
5t5y7ph7l104z
29 Sep 22
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
8:00am
8-K
EX-99.1
5xlht
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
r6dwmcm1ejaocz wunxc
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
u8maf f4x97a0qp9z2
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
EX-99.1
sdujxr4 9137
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
EX-99.1
n9kqp qlke84
5 Apr 22
VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program
8:00am
8-K
EX-99.1
j6qltd5uzuw
7 Mar 22
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022
8:00am
8-K
EX-99.1
2u3ik
8 Nov 21
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides
8:00am
8-K
EX-1.1
n692eukxzvlnalxwkhb7
3 Sep 21
Entry into a Material Definitive Agreement
8:53am
424B5
39cwka4sl5b3u4wm8
3 Sep 21
Prospectus supplement for primary offering
8:01am